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To expedite the timely creation of medical practice guidelines, a meta-analytic method was 
developed to combine of both dichotomous survival data and continuous physiologic data from 
multiple studies comparing the same innovative clinical intervention to standard care.  The 
method is adapted for synthesis of small, early studies of novel treatments.  An aggregate ratio, 
R*, of the observed treatment effect to a clinically optimal treatment effect for studies in a series 
is computed, and compared to the 95% confidence limit for R* under the null hypothesis.  
Weights assigned to each study may reflect its precision, quality, or clinical relevance.  Input 
data for continuous variables include sample means, standard errors, and sample sizes.  Input 
data for dichotomous variables include group proportions and sizes.  The analysis can be done 
using a simple, one-page spreadsheet.  It allows one to judge biological significance, to test for 
statistical significance, to compare subgroups of studies for differences (heterogeneity of effect), 
to test for outliers, and to compute the power of the meta-analysis.  These features are 
demonstrated for studies of interposed abdominal compression—cardiopulmonary resuscitation 
(IAC-CPR).  This novel method of meta-analysis can provide rapid, quantitative, and accurate 
estimates of the amount of benefit or harm from an experimental clinical intervention, as 
reported in multiple small independent studies of differing experimental design. 
 
Key words (not in title): abdominal, cardiopulmonary resuscitation, confidence intervals, 
continuous, data interpretation, evidence-based medicine, interposed abdominal compression 




Abbreviations: CPR, cardiopulmonary resuscitation, IAC, interposed abdominal compression, 






The fruits of research are sometimes like apples and oranges, i.e. they are not directly 
comparable.  This paper presents a general approach to the systematic analysis of two-treatment 
experiments including a wide variety of study designs and end-points.  Such heterogeneity is 
typical of early research on an emerging therapy or concept, before experimental methods 
become standardized.  The approach was designed specifically as an aid to the evaluation of 
evidence during development of guidelines for CPR and advanced cardiac life support.  In this 
field multiple large clinical trials of new interventions are rare or nonexistent—owing to the lack 
of funding, the difficulty in obtaining informed consent from persons in cardiac arrest, the low 
probability of survival from sudden cardiac death, the perception that the existence of standards 
obviates the need for research, and the chaotic nature of the clinical setting during 
cardiopulmonary resuscitation.  Studies of innovative techniques in CPR include small numbers 
of patients.  Some focus on survival; others focus on physiologic end-points such as blood 
pressure.  Similarly, research synthesis relating to rare or orphan diseases, including many 
pediatric conditions, often involves a paucity of heterogenous data.  In these cases there is an 
insufficient number of large controlled clinical trials to justify a formal Cochrane review
1
. Yet 
patients must be treated anyway, and hence there will always be a need for clinical guidelines 




An important early question in analysis of a new treatment or intervention in such data poor 
areas of research is "does the new method work any better than the standard approach?"  An 
important related question is "does the new method work better in some subgroups of patients 
than in others?"  Quantitative statistical methods such as meta-analysis can help answer these 
questions
4
.  The novel meta-analytic method presented herein is applicable to any studies that 
compare a new clinical intervention (drug, dose, or device) with a standard or control 
intervention in diverse animal or clinical models.  Outcome measures may differ greatly.  Some 
may be continuous data (e.g. physiologic measures like end-tidal CO2 concentration or mean 
coronary perfusion pressure).  Others may be dichotomous data (e.g. integer head counts of 
patients resuscitated, discharged, etc.).  It is only necessary that all of the studies relate to a 
common focused question or test the same hypothesis and that the results of the different 
measures are generally consistent.  (If the patients die with "good numbers" for continuous 
physiologic data, then, obviously, the survival data and the "numbers" are inconsistent, and 
caution is necessary in combining them.) 
 
                                                   
*
 The author has been personally involved in guideline creation in orphan research areas as Chair of the Research 
Working Group, Emergency Cardiovascular Care (ECC) Programs, American Heart Association for the years 2000 
to 2002.  This committee was charged with developing methods of evidence evaluation used in creation of 
international guidelines for cardiopulmonary resuscitation and emergency cardiovascular care
2
  The present work 
was inspired by the challenges faced by the ECC committees, which had to make the most efficient possible use of 
available data.  The ECC committees began with traditional vote counting procedures, in which each positive 
significant study “casts a vote” for, and each non-significant study “casts a vote” against, a proposed innovation.  
This approach is, of course, strongly biased toward the conclusion that the experimental treatment has no effect.  
Hence vote counting methods are no longer recommended for the task of research synthesis
3-5
.  The present paper is 
an outgrowth of the author's search for a better alternative. 
 3 
Existing statistical methods are not satisfactory for this task.  A simple sign test of the numbers 
of studies having any observed positive effect of treatment, versus those with any observed 
negative effect of treatment can be done.  However, this approach ignores information about the 
magnitudes of treatment effects.  Conventional statistical tests using pooled data such as a t-test 
or analysis of variance assume homogeneity of variance, which is unlikely to be true in multiple 
small trials.  Accordingly, such tests are usually deemed inappropriate for the purpose of 
combining results in a meta-analysis
5
.  Conventional meta-analysis using effect size for 
continuous variables
5
 will not work, without modification, for dichotomous data such as the 
proportion of survivors.  Conventional meta-analysis using odds ratios
6, 7
 will not work for 
physiologic data like blood pressure or blood flow.  None of these methods deals formally with 
the issue of biological significance. 
 
The method meta-analysis, described herein, is an extension of the response ratio method 
developed by Hedges and coworkers for synthesis of continuous data from studies in the field of 
ecology
8
.  It permits assessment of the statistical and biological significance of the combined 
results from multiple small studies, which may include a mixture of continuous and dichotomous 
end-points.  It is straightforward and easily implemented on ordinary personal computers using 







Definitions of symbols used to describe input data for the analysis are given in Table 1.  The 
symbols E  and C  refer to sample means of continuous data, such as end-tidal CO2 , from 
experimental and control groups, respectively.  The symbols Ep  and Cp  refer to proportions 
obtained from experimental and control groups, such as the proportions of surviving patients.  
True population variances for a random variable, X, are indicated by the symbol )X(
2 .  
Estimates of population variances, obtained from measured data, are indicated by the addition of 
a “hat” symbol, )X(ˆ
2 .  Standard errors of the mean are indicated by a combined symbol, for 
example )E(̂ .  For continuous data )E(̂  and )C(̂  are taken as the published values for the 
standard errors of the mean reported by the investigators for treatment and control groups.  If 
these values are not provided, they can be calculated using formulas in Table 2.  For 
dichotomous data )p(ˆ E  and )p(ˆ C may be computed from the expression for the variance of 
the binomial distribution, )1n/()p1(p)p(ˆ
2  .  Division by  n-1  rather than by  n  provides 
an unbiased estimate for the variance
9
.  For simplicity of notation, "hats" are not used for sample 








Definition for continuous data Definition for dichotomous data 
E  
 
Sample mean for treatment group  
C  Sample mean for control group  
Ep  
 
 Proportion of individuals with favorable 
outcome in the treatment group 
Cp  
 
 Proportion of individuals with favorable 
outcome in the control group 
I Ideal result for a clinical study, the 
best possible outcome 
Ideal result for a clinical study, the best 




Number of subjects in experimental 
group 
Number of subjects in experimental group 
nC 
 
Number of subjects in control group Number of subjects in control group 
)E(̂  
or 
)p(ˆ E  
 
 
Published standard error of the mean 
for the experimental group 
(experimental group standard 
deviation divided by En ) 
)1n/()p1(p EEE  , estimate of the 
standard deviation of observed proportions in 
multiple replications of the same study 
)C(̂  
or 
)p(ˆ C  
Published standard error of the mean 
for the control group (control group 
standard deviation divided by Cn ) 
)1n/()p1(p CCC  , estimate of the 
standard deviation of observed proportions in 






























































Summarizing Research Findings as Clinical Result Ratios. 
 
Clinical result ratios for two-group experiments are computed as shown in Table 2.  They are 
obtained by dividing the measured difference in outcome between experimental and control 
groups by the clinically optimal difference in outcome for any particular end point.  The 
clinically optimal or ideal outcome, denoted  I , would usually represent return to normal 
physiologic status (for example, normal cardiac output or normal arterial blood oxygen content) 
or 100 percent survival in the case of proportions.  Hence, the clinical result ratio is either  
 
R =    CICE             (1a) 
 
in a study with continuous physiologic end points or  
 
R =    CCE pIpp           (1b) 
 
in a study of discrete endpoints such as survival.  The result ratio, R, for each individual study 
can be interpreted as a fraction of the best possible treatment effect that could have been found.  
By convention outcomes are described as positive, such that a larger value indicates benefit.  In 
turn, a ratio R > 0 indicates greater benefit in the experimental group than in the control group.
*
  
R = 1 indicates ideal benefit.  R = 0 indicates no benefit.  R < 0 indicates a worse result than 
control.  Zero values for E  , C  , Ep , or Cp  are allowed.  Note that the ideal outcome, I, in 
expression (1a) is almost surely greater than the control group outcome, C ; otherwise the study 
would not have been done.  In expression (1b) the value of  I  is typically 1.0 or 100 percent 
survival, which usually indicates the maximum possible clinical benefit.  However, it is not 
strictly true that the ideal survival is always 100 percent.  For example, in long-term studies the 
value of ideal outcome, I, could be taken as the predicted survival of healthy persons over the 
same time period.  (Although a common convention in statistics is to use upper case letters to 
denote random variables and lower case letters to denote constants, in the present context  I  is a 
constant.)  Using the ideal result, I, as a point of reference allows one to combine clinical 
response ratios for measures that have quite different scales and dynamic ranges.  Since the 
relative effect of treatment across studies is more constant than the absolute effect
11-13
, use of 
such response ratios is an advantage in meta-analysis. 




, outcomes are often reported as negative, e.g. mortality.  Such results are easily translated into 
survival.  It is an interesting mathematical diversion to show that if I=100 percent for survival and I'=0 percent for 
mortality, then R values computed directly from mortality data are the same as those computed from survival data.  
Although experts may disagree somewhat on the definition of "ideal", small changes in the choice of the parameter, 
I, do not influence the results of significance testing, as detailed in the Discussion section. 
 6 
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*For continuous data the estimates of the experimental and control group variances, namely 
 
 










)E(ˆ  and 
 












are usually provided in the reports of studies to be synthesized.  If not they must be calculated 





One practical issue in the computation of response ratios deserves mention here.  For the purpose 
of meta-analysis it is useful to use a single composite figure of merit to describe the treatment 
effect in each particular study in a series.  However, in many studies several different outcome 
measures are reported (primary and secondary end-points), which may have somewhat different 
ratios of experimental to control results.  There are two approaches to this situation
14
.  The first 
approach is to select a “best” end-point from each study that is most relevant to the question in 
hand.  This may well be the primary end point identified by the original investigators.  To avoid 
throwing away information in a data poor research area, however, it may be helpful to derive a 
composite measure of treatment effect for each such study.  Hence a second approach is to 
compute an average composite R-value to represent the overall result of each study.  (The 
general solution to this problem is to use a weighted average of outcome measures within each 
independent study, based on a predetermined framework defining the importance of the different 
measures reported.  The first approach, just described, is the special case in which the "best" 
 7 
outcome measure is given weight 1.00 and the all other measures are given weight zero.  The 
second approach requires treating the various within-study outcomes as correlated measures, for 
which the standard deviation of the average is the average standard deviation.) 
 
The result of this first phase of data abstraction is to create a single composite outcome measure, 
R, for each independent study.  These individual indices of effect can then be combined into an 
aggregate index for the entire series of studies. 
 
 
The Aggregate Response Ratio and its Distribution Under H0. 
 
The objective of this section is to develop a test statistic from the combined response ratios from 
multiple studies that has a known sampling distribution under the null hypothesis, H0.  Then 
significance testing for a meta-analysis will be possible.  First we shall find well behaved test 
statistics describing each individual study, and then we shall consider a weighted average of 
these statistics across all studies in the meta-analysis. 
 
Statistics for individual studies 
 
Suppose one has assembled a series of  m  independent studies of a particular treatment and has 
computed the clinical result ratio, R, for each study.  To obtain a test statistic with a known 
distribution under H0 , it is helpful to express result the ratio R for any particular study in terms 
































          (1d) 
 
and then to determine the distribution of R' values under the null hypothesis.  Because the 
distribution of ratios of random variables is skewed, it is standard practice to work with the 
logarithms of ratios, which have a more symmetrical distribution that is better approximated by a 
normal distribution
15, 16
.  (Of course, to work with logarithms we must have R' > 0.)  Under the 
null hypothesis, when the expected values of the numerator and denominator of R' are equal, and 
the coefficients of variation of the numerator and denominator of R' are also equal, then the 
natural log of R' is very well approximated by a normal distribution having zero mean and 
having variance given in Appendix 1 (A1.1).  As shown in Appendix 1, the variance of log R' 
can be determined directly, whereas the variance of R cannot, because the numerator contains the 
difference of two random variables.  The distribution of log R' is also very close to normal under 
H0 (Appendix 1(b)).  Moreover, the Central Limit Theorem provides a further argument for 
approximate normality of the average logarithm of R' across studies, which will be used for 
significance testing in the meta-analysis. 
 
 8 






























ln)'Rln(          (2b) 
 
 for dichotomous data in any particular study.  Under the null hypothesis, H0 , the mean value of 
the distribution of  = ln(R') is zero ( ln(1) = 0 ), and the estimated standard deviation is )(ˆ  , as 
defined in Table 2 and derived in Appendix 2.  Because the distribution of  is symmetrical and 
approximately Gaussian, one can readily compute the distribution of  e1'R1R  and its 
95 percent confidence limits. 
 
An aggregate test statistic for meta-analysis 
 
Now to conduct a meta-analysis of studies related to a common experimental intervention, one 
may define a pooled test statistic for a series of  m  independent studies as 
 
 e1*R ,           (3) 
 










          (4) 
 
with individual study weights wj, and  W  equal to the sum of the weights.  The virtue of using 
R* for meta-analysis is that confidence limits can be obtained for this statistic under H0, based 
upon the known, approximately normal distributions of the random variables j. 
 
The weights can be assigned with due caution and good judgment
17, 18
 to reflect the relevance or 
the quality of the studies.  Generally, precise guidelines should be drawn up in advance.  One 
option is to set all weights equal to 1, in which case W = m .  In this case all studies that are 
deemed relevant to the question at hand are given weight 1 , and all studies that are deemed 
irrelevant are given weight zero.  Another popular option is the use of inverse variance 
weighting, which gives greater weight to experiments whose estimates have greater statistical 
precision.  Inverse variance weights produce minimum variance of the overall weighted 
average
19, 20
.   
 
A formal process of assigning weights makes the relative contribution of each study explicit.  In 
addition, the explicit weights in expression (4) make it technically easy to repeat a meta-analysis 
with each study in turn omitted.  One simply sets the weight of each study temporarily to zero 
and observes the effect upon the results.  Such an exercise helps to determine if any one study 
 9 
drives the final conclusions of the meta-analysis.  The use of weights also expedites the 
comparison of subgroups of studies, as subsequently explained. 
 
To test R* for statistical significance and to make cumulative meta-analysis plots we wish to find 
95 percent confidence limits associated with R* when the null hypothesis is true.  This task is 
easily done as follows.  The estimated variance of   is  
 










22   .     (5) 
 
Expression (5) derives from the general principle that the variance of the sum of independent 
random variables is equal to the sum of the variances.  Here the component -values are 
obviously independent, since they come from different studies, each of which must include 
different subjects.  The variance estimates for the -values from each study are computed from 
measured data as shown in Table 2, the expressions for which are derived in Appendix 2. 
 
If we assume that under the null hypothesis   has a normal distribution with mean value zero 





 has a standard normal distribution.  In turn, 
the 95 percent confidence interval under the null hypothesis for    is S96.10 .  Hence, the 
lower and upper critical values for significance testing of R* with  = 0.05 are  
 
 S96.1L e1C    to   S96.1U e1C  .        (6) 
 
By calculating the empirical R* value and comparing it to the critical values  S96.1e1  , one 
obtains a rapid test of significance for biologically meaningful effects of treatment in the entire 
series of  m  studies.  (Note that the confidence interval for the mean log R' value is symmetrical, 
but the back-transformed confidence interval for R* is not.)   
 
Alternatively, one may calculate the classical p-value for the two-sided test H0:  = 0 vs. H1   









                                                   
** A virtue of the log transformation is that the log result ratios are approximately normally distributed.  
Further, by virtue of the central limit theorem21, an average of several log result ratios is even better 
approximated by a normal distribution.  Because )(ˆS   is actually an estimate derived from sample 
data, and hence a random variable, the distribution of  S/   will resemble a t-distribution.  However, one 
can show, along the lines of Welch
22
, that  S/   is distributed very much like a t-distribution with a 
number of degrees of freedom roughly equal to the number of patients in all studies synthesized.  Thus for 
a typical meta-analysis assumption of a normal distribution is very reasonable. 
 
 10 
Power of the Meta-analysis. 
 
Under H0 the mean value of the distribution of   is zero ( ln(1) = 0 ), and the standard deviation 
is  S, computed from expression (5).  Because the distribution of   is normal, one can also 
calculate the power of the meta-analysis for an alternative hypothesis, H1, that the true effect is at 
least, say, 10 percent of the ideal benefit, and assuming that S is the same under these 
circumstances, which is very nearly true.  (Under H1 there is a slight skewness to the distribution 
of  , which can be ignored in power calculations.)  Then, for R = 0.1 the mean value of    is 
given by 

 e11.0R   or  105.0)9.0ln(  .  (Note   is negative for a positive 
treatment effect.)  In this case the beta error, or probability of a false negative evaluation of the 








dx)x(f ,          (7) 
 
where f(x) is the probability density function for the normal distribution, and 0 .  The power 
of the meta-analysis is 1 - .  The usefulness of computing the statistical power of a meta-







Using the graphical approach similar to Lau and coworkers
7, 24
 one can construct a cumulative 
meta-analysis plot showing successive values of  
 e1*R   in relation to the critical values for 
rejection of the null hypothesis after publication of each study in the series being analyzed.  Such 




Omitting Individual Studies. 
 
Critics will often object to one study or another on technical grounds, raising the question as to 
whether the entire analysis is flawed because an offending study has been included.  To explore 
the influence of individual studies on the conclusions of the analysis one can make a table of the 
aggregate  R*  statistics and their confidence limits, first when no study, and then when each 
study in turn is omitted from the analysis by setting its weight, w, equal to zero.  If the results do 
not differ substantially (the usual outcome) then one can conclude that no single study drives the 
conclusions of the analysis. 
 
 
Comparing Subgroups of Studies for Heterogeneous Effects. 
 
Suppose one finds among the studies in a meta-analysis two apparent subgroups of studies that 
differ in treatment effect, possibly on the basis of differences in patient populations, treatment 
implementation, or hospital setting.  To test whether there is there a significant difference in the 
 11 
treatment effect between the subgroups one can re-do the meta-analysis twice—first setting the 
weights for subgroup 2 to zero, leaving subgroup 1, and then setting the weights for subgroup 1 
to zero, leaving subgroup 2.  The difference in mean log(R'), namely 21d   , between 
subgroup 1 and subgroup 2 can be tested for statistical significance.  Since, the subgroups are 







1  , which are automatically available from the separate meta-analyses 
of the subgroups.  The expected standard deviation of subgroup differences is 2
2
2
1d SSS  .  In 
turn, the 95 % confidence interval for  d  is 0  dS96.1 under the null hypothesis that d = 0.  If the 
observed  d  lies within this confidence interval, there is no significant difference between the 




Test for Outliers. 
 
If the difference, d, between a subgroup of m=1 study and the remaining m-1 studies is clearly 
significant, for example, if the absolute value of  d  is greater than, say, 3 times dS , then the 
study may be unidentified as an outlier. 
 
 
Spreadsheets for Performing Meta-analysis. 
 
A standard spreadsheet program such as Microsoft Excel is sufficient to perform a meta-analysis 
of clinical response ratios.  No macros or programming are needed.  Costly special purpose 
software is not required.  There are two general phases of calculation.  The first is obtaining the  
R- and  -statistics for each study.  The second is running the meta-analysis itself.  These phases 
can be performed in different sections of the spreadsheet, as shown in Tables 3 and 4.  These 
tables were copied directly form a working spreadsheet, a template for which can be obtained 
from the author at no cost
**
 and modified for similar meta-analyses of various topics. 
 
 




During interposed abdominal compression (IAC)-CPR manual pressure is applied to the 
abdomen of the victim 180 degrees out of phase with the rhythm of chest compression, so that 
the abdomen is being compressed when chest pressure is relaxed, and vise versa.  This technique 
has been studied in a variety of mathematical, mechanical, animal, and clinical models with 
generally positive results
25
.  For simplicity only human studies are included in the present meta-
analysis.  These relatively small, initial studies gathered a mixture of continuous physiologic data 
and dichotomous survival data, which are well suited for analysis in terms of clinical response 
ratios.  Full length, peer reviewed publications were identified using evidence evaluation 
                                                   
**
 E-mail: babbs@purdue.edu 
 12 
worksheets created by the research working group of the American Heart Association
26
.  
Individual trials were obtained from MEDLINE searches, the author’s files, and reference lists of 
review articles on newer techniques in resuscitation as referenced in
2
.   All studies compared 
patients receiving IAC-CPR with those receiving standard CPR.  The end points analyzed 
include blood pressure, end tidal CO2, frequency of return of spontaneous circulation, and 
frequency of hospital discharge with intact neurological function.  Altogether there are 7 separate 
results reported in the 5 studies.  Criteria for quality and relevance of the studies are defined in 
terms of "Levels of Evidence", developed by the American Heart Association and described in 
detail previously
26
.  The four Level 1 studies are weighted 1, and the one Level 2 study is 
weighted 1/2.  The reduced weight for the Level 2 study is a conservative choice, since this 
initial non-randomized trial had strongly positive results. 
 
 
Composite  values for individual studies.   
 
Results of data reduction for the 5 available clinical studies of IAC-CPR are shown in Table 3.  
Successive studies are arranged by columns from left to right.  The column for the fourth study 
(Sack, 1992) is subdivided to accommodate multiple dichotomous end points.  Data from each 
study are entered in two blocks—the upper block for continuous data and the lower block for 
dichotomous data.  In Table 3 continuous data include mean arterial pressure and end-tidal CO2, 
which is reflective of forward blood flow.  Control and experimental means and their respective 
standard errors appear in successive rows.  Next the experimental/control result ratio, R,  and the 
more normally distributed logarithm of 1-R, denoted ,  are computed, together with the variance 
estimate for    using the formula shown in Table 2 and Appendix 2 (A2.5a). 
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Table 3.  Raw and composite outcome data from independent human studies of IAC-CPR* 
 
Study ID Berryman Mateer Ward Sack 1** Sack 2 
Date 1984 1985 1989 1992 1992 
       
Continuous Data       
       
End point MAP  ET-CO2    
Con mean 26  9.6    
Con SEM 1  1    
Exp mean 39  17.1    
Exp SEM 1.6  1.5    
Con N 6  33    
Exp N 6  33    
R 0.1884   0.3676    
R' 0.812   0.632    
Grand Mean 32.5   13.35    
= ln(R') -0.209   -0.458    
V() 0.000911   0.0117    
       
Dichotomous Data       
       
End point  ROSC ROSC ROSC Discharge ROSC 
Con survivors  45 3 14 3 21 
Con N  146 17 55 55 76 
Exp survivors  40 6 29 8 33 
Exp N  145 16 48 48 67 
Con p  0.3082 0.1765 0.2545 0.0545 0.2763 
Exp p  0.2758 0.375 0.6041 0.1666 0.4925 
R'   1.04677 0.7589 0.531 0.88141 0.70122 
R   -0.04677 0.2411 0.469 0.11859 0.29878 
Grand p   0.292096 0.2727 0.41748 0.1068 0.37762 
  
0.045713 -0.2758 -0.633 -0.1262 
-
0.35493 
V()  0.005711 0.0484 0.02852 0.00476 0.01728 
       
Composite Data       
       
Mean  -0.2087 0.0457 -0.3671 xxx -0.3796 -0.3549 
Mean V() 0.00091 0.00571 0.0301 xxx 0.01664 0.01728 
 
*Abbreviations: Con = control, Exp = experimental, ET-CO2 = end tidal carbon dioxide 
concentration, hits = number of patients with favorable outcome, ID = identifier, MAP = mean 
arterial pressure, N = number of patients in a group, ROSC = return of spontaneous circulation, 
SEM = standard error of the mean 
** Two columns accommodate two dichotomous variables, ROSC and discharge survival.  
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The lower block in Table 3 is for dichotomous survival data, including return of spontaneous 
circulation (ROSC) and discharge survival.  The nature of dichotomous data requires different 
summary statistics.  Numbers of good outcomes (“survivors”) in both control and experimental 
groups and the respective group n’s are tabulated, together with associated proportions.  The 
variance estimate for the log result ratio with dichotomous data is computed from observed 
proportions as shown in Table 2 and Appendix 2 (A2.5b). 
 
A key feature of the meta-analysis is generation of a single figure of merit, describing the result 
of each independent study.  In Table 3 the mean log result ratio for all end points within a study 
is used to create such an estimate of treatment effect.  Similarly, the mean variance estimate for 
all end points within a particular study is used to create an estimate of the typical variance of the 
result ratio for that study.  This variance estimate is suitable for highly correlated variables 





Results of cumulative meta-analysis for IAC-CPR are shown in Table 4 and in Figure 1.  Table 4 
is a continuation of the same spreadsheet shown in Table 3.  The composite -values and their 
variances at the bottom of Table 3 for each of the 5 independent studies, involving entirely 
different patients, are transferred to the upper rows of Table 4 for each study.  Here, working 
from left to right, a weighted mean -value and its estimated standard deviation are found using 
expressions (4) and (5).  Successive columns from left to right represent successive stages of the 
cumulative meta-analysis.  The mean -value under Study 1 describes the first study only.  The 
mean -value under Study 2 describes the combined results of the first two studies.  The mean -
value under Study 3 describes the combined results of the first three studies, etc.  Subsequent 
rows of R* data and associated critical values are obtained from the mean  data by exponential 
transformation using expressions (3) and (6).  Note that the power of the over-all analysis to 
detect an R* of 0.1 or greater increases substantially after publication of the third study (Table 4, 
bottom).  Such calculations of beta error and statistical power can be useful to evaluate the 




Table 4.  Cumulative meta-analysis of human studies of IAC-CPR 
 
 Study  1 Study  2 Study  3 Study  4 Study  5 
Study  Weight 0.5 1 1 1 1 
Study Number 1 2 3 4 5 
Composite  -0.2088 0.0457 -0.3671 -0.3796 -0.3549 
Composite V() 0.0009 0.0057 0.0301 0.0166 0.0173 
Weight* -0.1044 0.0457 -0.3671 -0.3796 -0.3549 
Weight2*V() 0.0002 0.0057 0.0301 0.0166 0.0173 
  -0.2088 -0.0391 -0.1703 -0.2301 -0.2578 
̂ ( ) 0.0302 0.0514 0.0759 0.0656 0.0588 
Ratio R* 0.1884 0.0384 0.1566 0.2055 0.2273 
Critical pt. -0.061 -0.10594 -0.1604 -0.13713 -0.1221 
Critical pt. 0.0575 0.09579 0.13825 0.12059 0.1088 
p-value 5E-12 0.44651 0.02488 0.00045 0.00001 
Beta 4E-07 0.88469 0.38849 0.06062 0.00761 




Figure 1 is a plot of the aggregate result ratio,  R*, and the associated critical values with 
publication of successive studies.  The left-most data point represents the historically first trial, 
the second a combination of the first two trials, the third a combination of the first three, etc.  
The separate lighter weight lines, without data points, are upper and lower critical values; they 
include the 95 percent confidence intervals for R* under the null hypothesis.  The data points and 
critical values plotted in Figure 1 correspond to the summary data in the columns of Table 4 
from left to right.  A significant aggregate effect of treatment in humans is achieved and 
maintained after the publication of the third study.   The effect of IAC-CPR is both biologically 
and statistically significant.  Biological significance can be judged from the absolute value of R*, 
here 20 percent of the ideal value of 1.0.  Statistical significance can be judged from the 













































Figure 1.  Cumulative meta-analysis of human studies of interposed abdominal 
compression CPR.  In this horizontal format solid data points represent successive 
aggregate R* values computed from the data.  The separate upper and lower curves 
represent critical values for statistical significance.  Under the null hypothesis data points 




Analysis with Studies Omitted. 
 
Table 5 shows results of meta-analysis of IAC-CPR when each of the 5 studies in turn is given 
zero weight.  No single study drives the conclusion that IAC-CPR produces statistically 







Table 5.  Effects of omitting single studies 
 
 Study omitted 
 None 1 2 3 4 5 
       
Ratio, R* 0.227 0.232 0.291 0.203 0.200 0.206 






Retrospectively, however, there does appear to be a difference between the four in-hospital 
studies and the one pre-hospital study of IAC-CPR.   When the weights of all other studies are 
set to zero, the R* value for the one out-of-hospital study (study number 2) is -0.05.  When the 
weight of study 2 is set to zero, the R* value for the remaining in-hospital studies is +0.29. A d-
test, as described in Methods, for the difference in log(R') shows that the difference is greater 
than 3 standard deviation from zero.  The failure of the one pre-hospital study to demonstrate a 
difference is explained by the substantial periods of standard CPR necessarily received by 
patients in the IAC-CPR group both before arrival of emergency medical personnel and during 
transport to the hospital
2
.  Thus there is strong evidence, in particular, for the use of IAC-CPR in 





To speed the translation of valid research findings into clinical practice, guideline writers must 
make the most efficient use of available data, using methods such as cumulative meta-analysis
7
.  
The present statistical approach is a form of cumulative meta-analysis applicable to both 
continuous and dichotomous data, which tend to crop up heterogeneously in emerging research 
areas and in studies involving less common disease entities.  Because the patients in one study 
are never compared directly with those in another study, it is not necessary to assume that the 
trials synthesized are exactly comparable (a Petonian approach
27, 28
)—only that they test the 
same basic intervention as it might be implemented in various settings in the real world.  Using 
clinical response ratios, the particular studies to be included in a meta-analysis can be selected on 
scientific and medical grounds, not on the basis of technical statistical requirements such as 
homogeneity of variance or the need to treat continuous and dichotomous data differently.   
 
There are a variety of other helpful aspects of working with clinical response ratios.  Clinical 
response ratios describe biologically meaningful effects of treatment, allowing synthesis of 
various end-points on a scale from 0 to 1.0, representing no improvement to maximal desirable 
improvement.  R* = 0 indicates absolutely no evidence of clinical benefit versus control.  R* = 1 
indicates maximal or ideal clinical benefit.  R* > CU indicates significantly better performance of 
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the experimental treatment than the control.  R* < CL indicates significantly poorer performance 
than control.   
 
Use of R* statistics rather than simple ratios of experimental to control end-points
8
 allows 
synthesis of measures with a wide variation in dynamic ranges, for example arterial blood pH, 
for which the biological range is about 7.1 to 7.6 versus arterial blood pO2, for which the 
biological range (including 100 percent oxygen breathing) is about 40 to 400 torr.  A strength of 
the present method of meta-analysis is that the test of the null hypothesis itself does not depend 
on the fixed effect assumption.  There is no formal requirement that the components of   in 
expression (4) have the same mean or that they have the same variance.  It is simply an average 
of independent random variables.  However, these values are normalized to a biologically 
meaningful range by introduction of the ideal response factor, I. 
 
Importantly, the significance test for Type 1 error is not sensitive to small differences in expert 
opinion regarding the choice of the normal values, I.  This fact can be demonstrated numerically 




There may be some minor abuse potential in the choice of values,  I  , because there is some 
latitude in deciding what the ideal therapeutic response would be.  Typically changes of 
continuous variables from abnormal to the mid normal value would be reasonable choices for 
ideal therapeutic benefit.  Changes in dichotomous variables to 100 percent survival or response 
rates are similarly obvious choices.  It would be difficult for biased analysts to circumvent these 
obvious choices, which will be visible for readers to judge and dispute if they wish. 
 
A minor technical advantage of the present method using the ideal response factor over the 
simple response ratio method
8
 is that it can be used for experiments in which the mean control 
value is zero or near zero.  In such cases the denominator of the simple response ratio method 
would be too small. 
 
The general notion of combining various types of data in one analysis is based upon the idea that 
the first step in the generation of clinical practice guidelines is simply to determine if a proposed 
treatment, in general, produces favorable effects
27
.  If it does, then the effects that are seen in the 
selected trials are likely to generalize to the even broader range of circumstances found in 
widespread practice.  When data are abundant possible heterogeneity of treatment effect among 
                                                   
***
 The analytical result (given here without detailed proof) is that as the value of ideal outcome, 
I, is changed by a modest amount, I, the relative change in the upper limit for significance 






U  .  Accordingly, as I is changed, both the test statistic, R, and the critical value for 
significance testing, cU, increase or decrease by the same percentage.  Hence the result of the 
significance test is not influenced by small changes in I.  In outline, the proof includes 
differentiation of expression (1) with respect to I to obtain dR/R, use of the small value 
approximation of e
x






U  , then finding dS/S by 
differentiation of expression (5), and noting that the result is the same as dR/R. 
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sub-populations becomes a major question.  In the example of IAC-CPR, even with only five 
clinical studies to analyze, there is evidence that the method may be more effective for in-
hospital resuscitation than for out-of-hospital resuscitation.  In meta-analysis there seems to be a 
tradeoff between combining heterogeneous studies, which increases generalizability, and 
combining only homogeneous populations, which reduces variation but also reduces 
generalizability.  The use of an overall significance test, followed by subgroup analysis, allows 
one to do the former, followed by the latter, obtaining the benefits of both. 
 
The quality of any meta-analysis sis is heavily influenced by the quality of the studies included.  
Selection of studies depends greatly upon the viewpoint of the meta-analyst and the framing of 
the question to be addressed.  Selection also may depend on subjective ratings of study quality, 
which can vary greatly
17
.  Language bias may exclude trials published in languages other than 
English
29
.  Data can be double counted inadvertently, for example in a separate single-center 
report of some of the same patients that are included in a multi-center trial.  Studies with non-
significant results -- especially ones with small sample sizes -- may be less likely to be published 
(publication bias), and hence may not be accounted in a formal meta-analysis
29
.  Such biases can 
be minimized by a vigorous effort to include all relevant studies. 
 
The explicit weighting factors in expressions (4) and (5) for the various studies may be viewed 
negatively as easily abusable fudge factors that could be used to skew an analysis in one 
direction or another, depending on the bias of the reviewer
17, 18
.  In general, inclusion of all 
studies is recommended, using either equal weighting for quality 
5, 14, 30
 or inverse variance 
weighting
19, 20
.  The seeming arbitrariness of weights may be unsettling to those unfamiliar with 
meta-analysis.  If concern arises one can perform a sensitivity analysis by re-running the meta-
analysis with alternative weights and presenting the results in a table, similar to Table 5.  
Typically the main results of the meta-analysis will be insensitive to changes in the weighting 
scheme, giving the reader confidence that the weights were not chosen to produce a particular 
result. 
 
It is important to realize, however, that any synthesis of research findings will include the 
unavoidable selection bias of the reviewer, who must choose which studies to include and which 
to omit from the review (i.e. assigning weights equal to zero).  If the explicit weights were 
omitted from expressions (4) and (5), then all included studies would have weight 1 and all 
excluded studies would have weight zero.  The explicit weights merely highlight the necessary 
judgments required, forcing the reviewer to disclose subjective decisions.   
 
A weighting scheme of particular interest is the inverse variance weighting.  As shown by 
Hedges
19
, selecting weights that are inversely proportional to the variances of individual random 
variables minimizes the variance of their sum.  Such weights give the narrowest 95 percent 
confidence interval for the sum.  Inverse variance weighting is easily implemented in 
spreadsheets such as Table 4, because variances of study log R' values are already calculated as 






When used properly and wisely, meta-analysis of clinical response ratios is a flexible tool to 
expedite the timely and accurate syntheses of early research findings in clinical medicine.  In 
particular, meta-analysis may be used for combining studies in research areas where large 
clinical trials would not be practical or would be unethical—for example in the field of 
cardiopulmonary resuscitation where the issue of informed consent becomes quite difficult.  The 
present method provides quantitative tests of both Type 1 and Type 2 statistical errors, which 
would lead respectively to either false positive or false negative evaluations of emerging 
treatments, approaches, or concepts.  Such information can guide individual and institutional 
practice and shorten the time between research discoveries and their clinical implementation, 





Appendix 1.  Variance estimate for the logarithm of a ratio of random variables 
 
(a) Application of the delta method 
 
The probable error method or delta method
16, 32
 may be used to approximate variances of 
functions of random variables.  If  X  is a random variable with mean    and variance  2 ,  the 
variance   222 )(f)X())X(f(   where )X(f   is the first derivative of function f(X) with 
respect to X.  To appreciate the approximation one can visualize the function f(X) as a graph 
with a tangent of slope )(f   at point (, )(f  ).  By deduction from such a graph, it follows that 
the standard deviation of f(X) is approximately )(f   times the standard deviation of X, as long 
as )X(f   does not change greatly over the range of X. 







































 .  (A1.1) 
 
To explore limits of approximation (A1.1) and the shape of the distribution of ln(X/Y), a more 
detailed treatment is as follows. 
 
(b) Application of a series expansion 
 
Let X and Y be two independent random variables, each always > 0.  Let us represent X and Y as 
1xx UX   and 2yy UY  , where constants  x  and  y  are population means,  x  
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and  y  are standard deviations such that / < 1, and random variables  U1  and  U2  are 
distributed as N(0,1), that is  U1  and  U2  are independent standard normal deviates.  Now 












 ,         (A1.2) 
 
where cx  and  cy  are coefficients of variation (/), which are typically < 0.3 in order to keep X 
and Y > 0.  Now 
 






















 .     (A1.3) 
 







1ln  for 1 , which 

































ln  .    (A1.4) 
 
From inspection of the series expansion, the random variable (A1.4) equals a constant, 
 




x cc   (i.e. the combination of 1x Uc  and 
2y Uc ), plus a smaller correction term.  The variance of the first three terms is given by (A1.1).  
The correction term is the difference of two random variables that are distributed as U
2
, namely a 
chi-square distribution with one degree of freedom.   If cx = cy , then the distribution of the 
correction term will be symmetrical about zero, and the correction will add a small amount of 
extra noise or variance to the distribution of the normal approximation.  
 
Given that standard normal deviates 1 and 2 are independent, that U
2
 is not correlated with U, 
and that the variance of a chi-square distribution with 1 degree of freedom is 2, we have  
 






















 , or 
 
 









































ln .      (A1.5) 
 
If cx = cy  = c , then the ratio of the variance of the actual distribution to that of the approximation 
of (A1.1) is 1 + c
2
 .  For example if c = 1/4, then the variance ratio is  




1 , or about a 3 percent 
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difference.  Indeed, expression (A1.5) could be used to further refine variance estimates in Table 
2; although the correction would be small.  Thus when cx = cy the normal approximation to the 
distribution of ln(X/Y) is quite good. 
 
In contrast, however, if cx >> cy , or if cx << cy , then the mean value of the chi-square correction 
term  222y212x UcUc
2
1
  will be nonzero, introducing skewness as well as noise to the actual 
distribution of ln(X/Y).  In the limiting case, in which c = cx >> cy or cx << cy = c the amount of 




) = 0.5 c
2
, where the expected value of a chi-square 
distribution with 1 degree of freedom, E(U
2
), is 1.0.  For example, if cx = cy  = 0.25 for typical 
data, then the bias due to skewness would be 0.0625.  In practical meta-analyses the observed 
value of log response ratios ln(X/Y) may be in the neighborhood of  0.10 .  Thus, the effect of 
skewness can be a substantial fraction of the effect of experimental treatment when yx cc  .  For 
this reason variance estimates using (A1.1) and the assumption that ln(X/Y) is normally 
distributed apply most accurately to cases where the coefficients of variation of X and Y are the 




Appendix 2.  Variance estimate for the complement of the log clinical result ratio, R', for 
an individual study under the null hypothesis 
 






























ln)'Rln(  for dichotomous data.      (A2.1b) 
 
We wish to estimate the variance of the 's under the null hypothesis that there is no true effect 
of treatment on the sampling distributions for experimental and control data.  One can estimate 
the variance of the distribution of =ln(R') values, using the relationship  
 



























        (A2.2) 
 
derived in Appendix 1.  Note that A2.2 assumes that X and Y are independent, which is true for 
independent experimental and control groups in most clinical trials, because they contain 





































  . 
 



















          (A2.3a) 
 






  for dichotomous data,      (A2.3b) 
 
where EC nnN    is the total number of subjects in the study. 
 
For continuous data a well-accepted estimate of the common population variance under H0 is 
 










 ,      (A2.4a) 
 
which is a weighted average of the sample variance estimates, the weights being the respective 
degrees of freedom. 
 
For dichotomous data we assume that the true proportion of survivors under H0 is given by 
(A2.3b).  For binomial distributions the variances of control and experimental proportions 
depend upon the sample sizes nC and nE , which could be different
31
 ( p 234).  In this case an 











  .          (A2.4b) 
 











  .         (A2.4c) 
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Now using expressions (A2.3a) for P  and (A2.4a) for  Pˆ 2 , we can compute the desired 
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   .     (A2.5a) 
 
Similarly, we can compute the desired variance estimate for  derived from dichotomous data 










































 , where under H0 ppp CE  , and 
 
substituting expressions (A2.4b) and (A2.4c), we have for dichotomous data 
 



















1. The Cochrane Manual, www.cochrane.org. 2003. 
2. Cummins RO. American Heart Association in collaboration with the International 
Liaison Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation 
and emergency cardiovascular care: international consensus on science. Circulation 2000; 
102 (suppl I):I-1--I-384. 
3. Hedges LV, Olkin I. Vote-counting methods in research synthesis. Psychological Bulletin 
1980; 88:359-369. 
4. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Orlando: Academic Press, 
1985. 
5. Hunter JE, Schmidt FL. Methods of Meta-Analysis: Correcting Error and Bias in 
Research Findings. Newbury Park, California: Sage Publications, 1990:592. 
6. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of 
randomized controlled trials. N Engl J Med 1987; 316:450-5. 
7. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. 
Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 
1992; 327:248-54. 
8. Hedges LV, Gurevitch J, Curtis PS. The meta-analysis of response ratios in experimental 
ecology. Ecology 1999; 80:1150-1156. 
9. Babbs CF. Simplified meta-analysis of clinical trials in resuscitation. Resuscitation 2003; 
In Press. 
10. Sinclair JC, Bracken MB. Clinically useful measures of effect in binary analyses of 
randomized trials. J Clin Epidemiol 1994; 47:881-9. 
11. Walter SD. Variation in baseline risk as an explanation of heterogeneity in meta- 
analysis. Stat Med 1997; 16:2883-900. 
 25 
12. Engels EA, Schmid CH, Terrin N, Olkin I, Lau J. Heterogeneity and statistical 
significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med 2000; 
19:1707-28. 
13. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the 
control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat 
Med 1998; 17:1923-42. 
14. Wolfe FM. Meta-Analysis: Quantitative Methods for Research Synthesis. In: Lewis-Beck 
MS, ed. Quantitative Applications in the Social Sciences. Vol. 59. Newbury Park: Sage 
Publications, 1986:65 pages. 
15. Feller W. An Introduction to Probability Theory and Its Applications. Vol. 1. New York: 
John Wiley & Sons, Inc., 1957:461 pages. 
16. Beaton GH, Martorell R, Aronson KJ, et al. Effectiveness of vitamin A supplementation 
in the control of young child morbidity and mortality in developing countries. ACC/SCN 
State-of-the-art series--nutrition policy discussion paper. Vol. 13. Suffolk, England: 
Lavenham Press Ltd., 1993:120. 
17. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials 
for meta-analysis. JAMA 1999; 282:1054-60. 
18. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA. Incorporating variations 
in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992; 
45:255-65. 
19. Hedges LV. Estimation of effect size from a series of independent experiments. 
Psychological Bulletin 1982; 92:490-499. 
20. Hedges LV. Combining independent estimators in research synthesis. British Journal of 
Mathematical and Statistical Psychology 1983; 36:123-131. 
21. Mosteller F, Rourke REK. Sturdy Statistics: Nonparametrics and Order Statistics. 
Reading Massachusetts: Addison-Wesley, 1973:395 pages. 
22. Welch BL. The significance of the difference between two means when the population 
variances are unequal. Biometrika 1937; 29:350-362. 
23. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychological 
Methods 2001; 6:203-217. 
24. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of 
meta-analyses of randomized control trials and recommendations of clinical experts. 
Treatments for myocardial infarction. JAMA 1992; 268:240-8. 
25. Kern KB, Paraskos JA. 31st Bethesda Conference--Emergency Cardiac Care (1999). 
Journal of the American College of Cardiology 2000; 35:825-880. 
26. Cummins RO. Introduction to the international guidelines 2000 for CPR and ECC. 
Circulation 2000; 102 (suppl I):I-1--I-11. 
27. Peto R. Why do we need systematic overviews of clinical trials? Statistics in Medicine 
1987; 6:233-240. 
28. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after 
myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular 
Diseases 1985; 27:335-371. 
29. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin 
Epidemiol 2000; 53:207-16. 
 26 
30. Emerson JD, Burdick E, Hoaglin DC, Mosteller F, Chalmers TC. An empirical study of 
the possible relation of treatment differences to quality scores in controlled randomized 
clinical trials. Control Clin Trials 1990; 11:339-52. 
31. Altman DG. Practical Statistics for Medical Research. Boca Raton: Chapman & Hall, 
1991:611. 
32. Crumpler TB, Yoe JH. Chemical Computations and Errors. New York: John Wiley & 
Sons, Inc., 1940:174-179. 
 
 
